D&D Pharmatech (347850) Fundamentals 2026 — Revenue Analysis | SniperIQ
D&D Pharmatech (347850) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩2.58T, trading at ₩59000.00 on the KOE. This SniperIQ fundamentals page covers D&D Pharmatech's valuation, profitability (net margin -770.0%), revenue (₩4.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is D&D Pharmatech's market cap?
D&D Pharmatech (347850) has a market capitalization of approximately ₩2.58T, trading at ₩59000.00 on the KOE. Market cap moves with the live share price.
What is D&D Pharmatech's P/E ratio?
D&D Pharmatech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 34.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is D&D Pharmatech?
D&D Pharmatech runs a net profit margin of -770.0%, a gross margin of 8.4%, and an operating margin of -1188.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does D&D Pharmatech generate?
D&D Pharmatech reported revenue of ₩4.3B for fiscal year 2025, with net income of -₩23.6B and earnings per share (EPS) of -547.02. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does D&D Pharmatech pay a dividend?
D&D Pharmatech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is D&D Pharmatech financially healthy?
D&D Pharmatech carries a debt-to-equity ratio of 0.08x and a current ratio of 8.02x, with a market beta of 1.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is D&D Pharmatech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For D&D Pharmatech (347850) the key facts are: market cap ₩2.58T, revenue ₩4.3B, 52-week range 29375-116600. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track D&D Pharmatech's full fundamentals live
Get D&D Pharmatech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.